Myelofibrosis

Patients with myelofibrosis and other myeloproliferative neoplasms (MPN) are often able to achieve improved survival outcomes and quality of life following treatment with ruxolitinib (Jakafi), a highly potent and selective JAK inhibitor, alone and in combination with other drugs. Despite this, treatment options designed to address disease progression itself are […]